Speculative approaches in hypertension: concepts and drugs of the future.
Despite the availability and application of more effective antihypertensive drugs over the past 3 decades, hypertension continues to be a major risk factor for the development of premature cardiovascular disease. Moreover, failure to elucidate the pathogenesis of essential hypertension, noncompliance, and difficulties in defining the appropriate level of blood pressure elevation requiring therapy, continue to mitigate against the adequate control of hypertension. Some of these problems may be overcome by the availability of depot forms of antihypertensive medication or implantable drug delivery systems, or by the use of several recently developed antihypertensive drugs. These include dopaminergic agonists, selective alpha-adrenergic agents, calcium antagonists, medullary neutral lipids, gamma-aminobutyric acid agonists, and inhibitors of renin or phenethylamine N-methyl-transferase. In addition, the potential involvement of morphinomimetic peptides, prostaglandins, tonin, and bradykinin in blood pressure control or certain hypertensive states suggests that drugs developed to block or potentiate the actions of these substances may have important therapeutic applications.
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism; D005544:Forecasting; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008901:Mineralocorticoids / Q000037:antagonists & inhibitors; D010455:Peptides / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D011942:Receptors, Adrenergic, alpha / Q000502:physiology; D012106:Research; D000092502:Renin Inhibitors
D000959:Antihypertensive Agents; D001971:Bromocriptine; D004298:Dopamine; D008901:Mineralocorticoids; D010455:Peptides; D011453:Prostaglandins; D011942:Receptors, Adrenergic, alpha; D000092502:Renin Inhibitors